Lilly to present new clinical data for Verzenio (abemaciclib) and multiple novel pipeline programs at the 2025 European Society for Medical Oncology (ESMO) Annual Meeting

Primary overall survival analysis from the Phase 3 monarchE study of Verzenio (abemaciclib) in HR+HER2-, node-positive, high-risk early breast cancer to be presented as a late-breaking oral presentation Verzenio (abemaciclib; CDK4/6 inhibitor): In a late-breaking oral presentation, Lilly will share results from the landmark seven-year analysis of monarchE, including primary overall survival analysis and updated invasive disease-free survival and distant relapse-free survival, in patients with hormone recept ...